Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced

Personalis, Inc.

2025-Q3 EPS reported -$0.65 vs consensus -$0.28 ▼ miss (-128.7%)

Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.
Delivered 4,388 clinical tests, +26% sequential and +364% YoY; submitted third Medicare dossier for lung cancer.
FY 2025 revenue guidance narrowed to $68-73M (from $70-80M); clinical tests reimbursed cut to $1.5-2M from $3-6M.
Cash, cash equivalents and investments $150.5M; cash used in operations and capex $23.4M in Q3.
Q4 2025 revenue outlook $15.7-20.7M; pharma/services revenue $12-17M; population sequencing ~$3.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.